c-RET
Los inhibidores de c-RET se dirigen al protooncogén RET (Rearranged during Transfection), que codifica una tirosina quinasa receptora involucrada en el crecimiento, diferenciación y supervivencia celular. La activación anormal de la señalización de RET puede llevar a una proliferación celular descontrolada y resistencia a la apoptosis, contribuyendo al desarrollo de cánceres como el carcinoma medular de tiroides y el cáncer de pulmón de células no pequeñas. Inhibir c-RET puede inducir apoptosis en células cancerosas y es un enfoque prometedor en la terapia contra el cáncer dirigida. En CymitQuimica, ofrecemos una variedad de inhibidores de c-RET de alta calidad para apoyar su investigación en oncología, transducción de señales y apoptosis.
Se han encontrado 61 productos de "c-RET"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Fórmula:C23H27F4N3O4SPureza:99.23%Forma y color:SolidPeso molecular:517.54Ref: TM-T10624
1mg40,00€2mg54,00€5mg92,00€10mg127,00€25mg208,00€50mg311,00€100mg445,00€1mL*10mM (DMSO)92,00€RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Fórmula:C27H31FN10O2Forma y color:SolidPeso molecular:546.611RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Fórmula:C38H42N10O3Forma y color:SolidPeso molecular:686.81YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Fórmula:C58H63F3N12O9Forma y color:SolidPeso molecular:1129.19AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Fórmula:C22H21ClF3N7OPureza:98%Forma y color:SolidPeso molecular:491.9RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Forma y color:Odour SolidCofetuzumab
CAS:Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.Pureza:>95%Forma y color:LiquidPeso molecular:146.7 kDaCDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Fórmula:C29H26N4OPeso molecular:446.21066RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Fórmula:C22H22N6OForma y color:SolidPeso molecular:386.45PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Fórmula:C22H22FN5O2Forma y color:SolidPeso molecular:407.44RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Fórmula:C26H29N9Forma y color:SolidPeso molecular:467.57Zeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Fórmula:C56H56F6N8O12Forma y color:SolidPeso molecular:1147.098BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Fórmula:C28H27F4N3O4SPureza:99.87%Forma y color:SoildPeso molecular:577.59Ref: TM-T67733
1mg74,00€5mg160,00€10mg235,00€25mg424,00€50mg635,00€100mg924,00€1mL*10mM (DMSO)188,00€QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Fórmula:C53H54N12O4Forma y color:SolidPeso molecular:923.07Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Fórmula:C21H21FN6O3Pureza:99.94%Forma y color:SoildPeso molecular:424.43RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Fórmula:C40H44N10OForma y color:SolidPeso molecular:680.84RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Fórmula:C28H24F2N6O3Forma y color:SolidPeso molecular:530.525trans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Fórmula:C27H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:533.6Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFórmula:C27H32FN9O2Pureza:97.88% - 99.8%Forma y color:SolidPeso molecular:533.6WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Fórmula:C16H15N3O3Pureza:99.21%Forma y color:SolidPeso molecular:297.31BBT594
CAS:BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Fórmula:C28H30F3N7O3Pureza:99.57%Forma y color:SolidPeso molecular:569.58RET V804M-IN-1
CAS:RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Fórmula:C19H16N6OPureza:97.94% - 99.62%Forma y color:SolidPeso molecular:344.37Ref: TM-T8467
1mg35,00€2mg50,00€5mg74,00€10mg90,00€25mg157,00€50mg236,00€100mg334,00€200mg495,00€1mL*10mM (DMSO)82,00€TPX-0046
CAS:TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
Fórmula:C21H21FN6O3Pureza:99.95%Forma y color:SolidPeso molecular:424.43Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Fórmula:C29H31N7O3Pureza:99.89% - >99.99%Forma y color:SolidPeso molecular:525.6Ref: TM-T8222
2mg34,00€5mg49,00€10mg84,00€25mg166,00€50mg259,00€100mg477,00€200mg692,00€500mg1.035,00€1mL*10mM (DMSO)56,00€Pyrazoloadenine
CAS:Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Fórmula:C5H5N5Pureza:99.02%Forma y color:Beige PowderPeso molecular:135.13GSK3179106
CAS:GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nMFórmula:C22H21F4N3O4Pureza:99.8% - 99.90%Forma y color:SolidPeso molecular:467.41Treprostinil Sodium
CAS:Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Fórmula:C23H33NaO5Pureza:99.67% - >99.99%Forma y color:SolidPeso molecular:412.5SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Fórmula:C16H15N5Pureza:99.53%Forma y color:SolidPeso molecular:277.32Ref: TM-T16923
1mg46,00€5mg90,00€10mg144,00€25mg281,00€50mg447,00€100mg650,00€500mg1.369,00€1mL*10mM (DMSO)90,00€WHI-P180 hydrochloride
CAS:WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Fórmula:C16H16ClN3O3Forma y color:SolidPeso molecular:333.77AD80
CAS:AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Fórmula:C22H19F4N7OPureza:99.49% - 99.75%Forma y color:SolidPeso molecular:473.43Ref: TM-T4301
1mg44,00€5mg96,00€10mg138,00€25mg268,00€50mg439,00€100mg645,00€500mg1.333,00€1mL*10mM (DMSO)90,00€RET-IN-16
CAS:RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Fórmula:C31H29F3N8O2Forma y color:SolidPeso molecular:602.61RET-IN-15
CAS:RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H28N8O2Forma y color:SolidPeso molecular:496.56RET-IN-8
CAS:RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Fórmula:C27H30N6O3Forma y color:SolidPeso molecular:486.57RET-IN-12
CAS:RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Fórmula:C30H30F3N5O4Forma y color:SolidPeso molecular:581.59RET-IN-6
CAS:RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C30H29N7Forma y color:SolidPeso molecular:487.6RET-IN-22
CAS:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Fórmula:C29H31F3N6O4Forma y color:SolidPeso molecular:584.59XMD15-44
CAS:XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Fórmula:C29H29F3N4OForma y color:SolidPeso molecular:506.56DUN73423
CAS:DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Fórmula:C19H16N6OPureza:98.09%Forma y color:SolidPeso molecular:344.37TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Fórmula:C29H31F3N8OPureza:98%Forma y color:SolidPeso molecular:564.6RET-IN-3
CAS:RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.Fórmula:C18H21N5O2Pureza:99.52%Forma y color:SolidPeso molecular:339.39Ref: TM-T9673
1mg70,00€5mg149,00€10mg227,00€25mg427,00€50mg675,00€100mg1.035,00€200mg1.395,00€1mL*10mM (DMSO)165,00€RET-IN-23
CAS:RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Fórmula:C28H28FN11Pureza:97.46%Forma y color:SolidPeso molecular:537.59TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFórmula:C26H34N6O3SPureza:98.68%Forma y color:SolidPeso molecular:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Fórmula:C26H26N6O2Pureza:99.89%Forma y color:SolidPeso molecular:454.52RET-IN-13
CAS:RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.Fórmula:C32H33F4N5O3Forma y color:SolidPeso molecular:611.63NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Fórmula:C20H19N3OForma y color:SolidPeso molecular:317.38FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFórmula:C30H30D3N9OForma y color:SolidPeso molecular:538.66FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Fórmula:C25H22N4O5Forma y color:SolidPeso molecular:458.47RET-IN-5
CAS:RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).Fórmula:C29H26FN9OForma y color:SolidPeso molecular:535.57RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Fórmula:C27H26F2N8OForma y color:SolidPeso molecular:516.55RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFórmula:C22H17N3O5SForma y color:SolidPeso molecular:435.45
